Company / R&D Expense
TherapeuticsMD, Inc. R&D Expense History
FY2015-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$19.8M
FY2021
5-year range
$19.8M / $27.3M
FY2017-FY2021
Trend
-27.5%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 4 consecutive years, from $72M in FY2017 to $20M in FY2021.
Based on SEC 10-K filings.
$20M in FY2021 with a 5-year CAGR of -14.5%.
Declined from $34M to $20M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -28.4%
- 5-Year CAGR
- -14.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- TherapeuticsMD, Inc.'s r&d expense has declined for 4 consecutive years.
- 5-year CAGR of -14.5%, indicating a declining trend.
- In FY2021, r&d expense decreased 27.5% year-over-year.
- Peak r&d expense was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $19.8M | -27.5% |
| FY2020 | $27.3M | -19.4% |
| FY2019 | $33.9M | -37.2% |
| FY2018 | $53.9M | -25.1% |
| FY2017 | $72.0M | +66.7% |
| FY2016 | $43.2M | +218.9% |
| FY2015 | $13.6M | +201.7% |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026